Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully closed a public offering, raising gross proceeds of $6.9 million, which includes the full exercise of the underwriters' over-allotment option [1][2]. Group 1: Offering Details - The company sold a total of 1,922,764 common stock units, each consisting of one share of common stock and one Series I warrant, and 1,528,000 pre-funded warrant units, each consisting of one pre-funded warrant and one Series I warrant [2]. - The price per Common Stock Unit was set at $2.00, while the Pre-Funded Unit was priced at $1.999 [2]. - The Series I warrants have an exercise price of $2.00 per share, are exercisable upon issuance, and will expire five years from issuance [2]. Group 2: Management and Regulatory Information - Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for the offering, with Laidlaw & Company (U.K.) Ltd. acting as a co-manager [3]. - The securities were offered under a registration statement on Form S-1, which was declared effective by the SEC on August 20, 2025 [4]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted therapies that can deliver genetic medicines to distal disease sites [6]. - The company's proprietary Redtail platform utilizes an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, aiming to enhance the effectiveness of virotherapy [6]. - The lead candidate from the Redtail platform is currently in IND-enabling studies and targets non-small cell lung cancer, ovarian cancer, and other tumor types with significant unmet medical needs [7].

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully priced a public offering to raise $6 million, indicating strong interest from both existing and new investors despite challenging market conditions [1][2]. Group 1: Offering Details - The offering consists of 1,472,764 common stock units priced at $2.00 each, and 1,528,000 pre-funded warrant units priced at $1.999 each [2]. - Each common stock unit includes one share of common stock and one Series I warrant, while each pre-funded unit includes one pre-funded warrant and one Series I warrant [2]. - The Series I warrants have an exercise price of $2.00 per share and are exercisable upon issuance, expiring five years from issuance [2]. Group 2: Underwriting and Closing - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering, with Laidlaw & Company (U.K.) Ltd. acting as a co-manager [3]. - The underwriters have a 45-day option to purchase an additional 450,000 shares of common stock and/or warrants at the public offering price [3]. - The offering is expected to close on or about August 21, 2025, pending customary closing conditions [3]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for delivering genetic medicines to disease sites [6]. - The company's proprietary Redtail platform utilizes an engineered enveloped oncolytic virus for systemic delivery to metastatic sites, aiming to enhance the effectiveness of virotherapy [6]. - The lead candidate from the Redtail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [7].

Core Viewpoint - Calidi Biotherapeutics, Inc. announced a reverse stock split at a ratio of 1-for-12 to optimize market dynamics and broaden investor appeal, effective August 5, 2025 [1][2]. Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to disease sites, utilizing its proprietary Redtail platform [6][7]. - The Redtail platform is designed to create viral vectors that evade immune detection, allowing for effective delivery of virotherapy to tumor sites [6]. Reverse Stock Split Details - The reverse stock split will consolidate every twelve pre-split shares into one post-split share, with fractional shares rounded up to the nearest whole share at the participant level [3][4]. - The split was approved by stockholders on July 9, 2025, and by the Board of Directors on July 11, 2025 [2]. - The new CUSIP number for the common stock will be 320703 408 following the split [1]. Stockholder Information - Registered stockholders with book-entry shares will not need to take action to receive post-split shares, while those with shares in certificate form will receive instructions for exchanging their certificates [5].

Core Viewpoint - Calidi Biotherapeutics has entered into a definitive agreement for the immediate exercise of existing warrants, which will generate approximately $4.6 million in gross proceeds to advance its clinical programs and operational expenses [1][3]. Group 1: Warrants and Financial Details - The company will exercise certain outstanding Series A, B-1, C-1, D, E, and F Warrants to purchase up to 6,595,000 shares of common stock at a reduced exercise price of $0.70 [1]. - Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for this offering [2]. - The new warrants will also allow for the purchase of 6,595,000 shares at the same exercise price of $0.70, with a term of five and a half years [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance clinical and pre-clinical programs, as well as for ongoing operating expenses and working capital [3]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to disease sites [6]. - The company's proprietary Redtail platform is designed to create viral vectors that evade immune detection, allowing for effective delivery of virotherapy to tumor sites [6]. - The lead candidate from the Redtail platform targets non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [7].